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Abstract Filgrastim, a recombinant methionyl human
granulocyte colony-stimulating factor (G-CSF) (r-
metHuG-CSF), is efficacious in stimulating neutrophil
production and maturation to prevent febrile neutropenia
(FN) in response to chemotherapy. Because of its relatively
short circulating half-life, daily filgrastim injections are
required to stimulate neutrophil recovery. In an effort to
develop a long-acting form of filgrastim that was as safe
and efficacious as filgrastim but had a longer in vivo
residence time, a number of strategies were considered.
Ultimately, fusion of filgrastim to polyethylene glycol
(PEG) was selected. Following extensive analysis of con-
jugation chemistries as well as in vitro and in vivo char-
acterization of a panel of PEGylated proteins, a construct
containing a 20 kDa PEG moiety covalently conjugated to
the N-terminus of filgrastim was chosen for advancement
as pegfilgrastim. Pegfilgrastim is primarily cleared by
neutrophils and neutrophil precursors (rather than the kid-
neys), meaning that clearance from the circulation is self-
regulating and pegfilgrastim is eliminated only after neu-
trophils start to recover. Importantly, addition of PEG did
not alter the mechanism of action and safety profile com-
pared to filgrastim. Clinical evaluation revealed that a
single 6 mg dose effectively reduces the duration of neu-
tropenia and risk of FN in patients receiving chemotherapy.
This work demonstrates the benefit of using PEGylation to
generate pegfilgrastim, which allows for once-per-che-
motherapy cycle administration while maintaining similar
safety and efficacy profiles as those for multiple daily ad-
ministration of filgrastim. Approaches that may provide
advances for therapeutic agonists of G-CSF receptor are
also discussed.
Key Points
Evaluation of multiple PEGylated forms of filgrastim
identified pegfilgrastim, a 20 kDa polyethylene
glycol (PEG) fusion protein, as the construct with the
optimal balance of in vitro activity and in vivo
residence time.
Pegfilgrastim, having self-regulating clearance,
remains in circulation during chemotherapy-induced
neutropenia and is not eliminated until neutrophils
start to recover.
Clinical efficacy of pegfilgrastim is achieved with a
single 6 mg dose once-per-chemotherapy cycle.
1 Introduction
Granulocyte colony-stimulating factor (G-CSF) is an en-
dogenous hematopoietic growth factor that stimulates prolif-
eration and differentiation of neutrophil precursors and
increases survival and activity of mature neutrophils [1].
Neutrophils, the most abundant white blood cells in circula-
tion, play a critical role in innate immunity and also influence
the adaptive immune response. The protective role of neu-
trophils is demonstrated by the severe and sometimes fatal
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infections that are developed by patients with congenital or
induced neutrophil deficiencies; in these patients the risk of
infection is proportional to the extent of neutropenia [2].
Neutrophils are short-lived cells and remain in circula-
tion for only hours to a few days [3, 4]. To maintain supply,
approximately 107 neutrophils are produced each second,
requiring an estimated two-thirds of the bone marrow’s
hematopoietic space. This output requires the rapid pro-
liferation of granulocyte precursors [5], making them
highly susceptible to cell death in patients being treated
with cytotoxic cancer chemotherapy. The reduction in
neutrophil number during chemotherapy increases the risk
of infection and hospitalization, as well as the risk of re-
ducing the chemotherapy dose and/or delaying the che-
motherapy treatment [6]. As a consequence, severe
neutropenia can increase the risk of mortality both in the
short-term (due to infections) and long-term (due to re-
ceiving insufficient intensity of chemotherapy) [7–9].
To address the risk of complications associated with
neutropenia in patients receiving myelosuppressive che-
motherapy, recombinant methionyl human G-CSF (r-
metHuG-CSF; filgrastim) was approved by the US FDA in
1991. Filgrastim decreases the incidence of infection as
manifested by febrile neutropenia (FN) in patients with
non-myeloid malignancies receiving myelosuppressive
chemotherapy. Filgrastim has a relatively short circulating
half-life (3.5 h) [10], necessitating daily administration
until neutrophil recovery. Furthermore, filgrastim requires
bodyweight-based dosing (starting at 5 lg/kg/day) and
frequent monitoring of neutrophil counts [11], which in-
crease the challenge of compliance. To enhance the pro-
duct characteristics, a variety of approaches to develop a
long-acting version of filgrastim were considered and
tested. By adopting a systematic approach and following a
series of rigorous testing procedures, pegfilgrastim
emerged as a G-CSF that can significantly reduce the risk
of neutropenia and related complications with one admin-
istration per chemotherapy cycle [12–14].
Pegfilgrastim has been used in clinical practice since 2002,
and its efficacy and safety have been demonstrated in a variety
of tumor types and settings [15–18]. With the ongoing devel-
opment of other long-acting G-CSF molecules and the ex-
pected arrival of pegfilgrastimbiosimilars in the next fewyears,
there is increased interest in understanding the basis of the
structure–function relationship important for developing a
long-acting G-CSF. Although the development program of
pegfilgrastim has been described elsewhere [19], a detailed
overview of the early non-clinical work and the scientific ap-
proach taken to select PEGylation as the G-CSF conjugate is
lacking.The objective of this review is to describe the rationale,
clinical implications, and scientific data of the PEGylation
approach used in the development of pegfilgrastim.
2 Filgrastim
Clinical experience with filgrastim extends for more than
20 years, and has been reviewed extensively [1, 20]. The
initial approval was based on two randomized clinical
studies in patients with lung cancer that demonstrated that
filgrastim treatment significantly reduced the duration of
severe neutropenia, the number of days of hospitalization,
the incidence of antibacterial treatment, and the number of
chemotherapy dose reductions [15, 21, 22]. Filgrastim has
additionally been approved for use in patients with acute
myeloid leukemia, severe congenital neutropenia, AIDS-
associated neutropenia, and to speed neutrophil recovery in
cancer patients receiving bone marrow transplant. It is also
approved for patients undergoing peripheral blood pro-
genitor cell collection.
In patients undergoing chemotherapy, it is recom-
mended that filgrastim dosing start 24 h after the comple-
tion of chemotherapy and be continued daily until the
absolute neutrophil count (ANC) is C10 9 109 cells/L,
which, in some cases, may require one injection each day
for 10–14 days. To eliminate the need for patients to either
return daily to their treatment center or to self-inject, a
long-acting form of filgrastim was desired. Strategies to
extend the duration of action include prolonged delivery
(e.g., slow absorption from a drug reservoir) or half-life
extension (i.e., to maintain concentrations in the blood).
Filgrastim itself is relatively unstable for extended periods
of time at physiologic temperature and pH [23], making a
prolonged delivery option less desirable. Therefore, it was
preferable to pursue a form of filgrastim with a longer
elimination half-life; achievable by modulating the rate of
filgrastim clearance. The desired properties of a long-acting
filgrastim are summarized in Table 1.
Filgrastim, being a protein, can be cleared by prote-
olysis; however, its primary clearance pathways are re-
nal- and neutrophil-mediated; for the latter, after binding
of filgrastim to the G-CSF receptor (G-CSF-R) on neu-
trophils and neutrophil precursors, the filgrastim–G-CSF-
R complex is internalized and degraded. In neutropenic
individuals, neutrophil-mediated clearance is sig-
nificantly reduced, and renal clearance becomes domi-
nant. Therefore, if renal clearance could be eliminated or
significantly reduced while neutrophil-mediated clear-
ance was retained, the drug would remain in circulation
during neutropenia and be cleared only when the neu-
trophils start to recover, effectively resulting in a self-
regulating therapeutic. Strategies to reduce renal clear-
ance include making the protein larger, more elongated,
or more negatively charged as these attributes make the
protein less likely to be filtered by the renal glomeruli
[24, 25].
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3 PEGylation of Filgrastim
3.1 Selection of PEGylation to Improve In Vivo
Residence Time
Options for increasing protein size include introducing
novel glycosylation sites (glycoengineering) or fusing the
protein to another protein, such as an antibody or serum
albumin, or fusing the protein to a polymer such as poly-
ethylene glycol (PEG). Many of these options were con-
sidered and the factors influencing the selection of
PEGylation are summarized in Table 2. In particular, there
was a desire to maintain the filgrastim core protein and to
preserve the means of filgrastim production such that the
extensive safety profile could be preserved in a long-acting
molecule.
Table 1 Considerations for developing a long-acting form of filgrastim
Parameter Filgrastim properties Requirements of a long-acting filgrastim
Drug clearance
mechanisms
Subject to renal clearance
Subject to neutrophil-
mediated clearance
Elimination or significant reduction of renal clearance while retaining neutrophil-mediated
clearance, allowing the drug to remain in circulation during neutropenia and be cleared
rapidly only when the neutrophils start to recover. This molecule should be able to provide
an effective serum concentration of G-CSF for a complete chemotherapy cycle
Efficacy Reduces duration of severe
neutropenia
Reduces incidence of FN
Reduces infections
Reduces hospitalization
Efficacy should be equivalent to or better than that for filgrastim across a broad range of tumor
types
Safety Acceptable safety profile No additional or more severe on-target adverse events (e.g., bone pain)
No increase in immunogenicity
FN febrile neutropenia, G-CSF granulocyte colony-stimulating factor
Table 2 Possible strategies considered for increasing the in vivo residence time of filgrastim
Possible strategy Examples of other modified proteins
available around the time of pegfilgrastim
development
Factors considered for developing a long-acting filgrastim
Glycoengineering
Introduction of novel
glycosylation sites to the
recombinant protein
Aranesp
Recombinant erythropoietin with higher
amounts of sialic acid-containing
carbohydrate
Approved in 2001 for treatment of anemia
Successfully used to increase the half-life of erythropoietin
Would require re-development of the expression and
purification processes used for filgrastim, which may affect:
Inability to retain the established safety profile of filgrastim
Longer development time
Increased costs
Fusion to other proteins
Attachment of G-CSF to an
antibody Fc domain or
albumin
Enbrel
Recombinant TNF receptor fused to the Fc
region of an IgG1 antibody
Approved in 1998 to treat various
autoimmune disorders
Addition of the protein partner may necessitate a change in the
protein expression or purification process
Both the antibody Fc and albumin interact with other
endogenous proteins and this may affect G-CSF localization
and/or activity
PEGylation
Attachment of PEG to the
purified protein
Adagen
Adenosine deaminase fused to multiple
PEG molecules
Approved in 1990 for enzyme replacement
therapy
Oncaspar
L-Asparaginase fused to multiple PEG
molecules
Approved in 1994 as chemotherapy for
leukemia
Demonstrated to be clinically safe and effective for increasing
the half-life of other molecules
Would enable use of filgrastim as the starting material,
thereby keeping the same protein expression and purification
processes
Flexibility in properties of the new molecule due to the range
of PEG sizes and conformations possible
PEG polymers are relatively chemically inert
PEG may reduce immunogenicity, proteolysis, and protein
aggregation
G-CSF granulocyte colony-stimulating factor, PEG polyethylene glycol, TNF tumor necrosis factor
Development of a long-acting G-CSF 187
3.2 Physicochemical Properties of Polyethylene
Glycol
The PEGylation process involves the covalent attachment
of PEG polymers to mature, purified protein. By starting
with purified material there would be no need to change
the core protein or the protein expression system to ac-
commodate PEGylation. PEG molecules comprise re-
peating ethylene oxide units. The carbon–carbon and
carbon–oxygen bonds are mobile, and there are no addi-
tional large or bulky groups on the polymer chain; as a
result, the PEG molecules are highly flexible and tend to
occupy a large space. Furthermore, because the oxygen
interacts strongly with water, each ethylene oxide unit can
coordinate 3–7 water molecules [26], creating a dynamic,
hydrated polymer that is predicted to form a thick, flex-
ible layer across the surface of the protein. With the ad-
dition of this layer, the PEGylated protein occupies a
much larger volume than would be predicted based on the
combined molecular weight of the protein and polymer
alone. This effect becomes more magnified as the size of
the PEG molecule increases, such that a 17 kDa PEG
molecule has a similar size as a 66 kDa protein and a
50 kDa PEG molecule has a similar size as a 476 kDa
protein [27]. This increase in the size of the PEG–protein
conjugate increases the in vivo residence time as has been
demonstrated for interferon IFN-a-2b conjugated to a
panel of PEG molecules with increasing molecular weight
[28]. With the addition of PEG moieties of 10, 20, 30 and
45 kDa, the hydrodynamic radius (cumulative radius of
the protein and PEG polymer) increased from *2 nm for
unconjugated IFN-a-2b to 5.7, 7.4, 9.1, and 9.6 nm for
the 10, 20, 30, and 45 kDa–PEG conjugates. The asso-
ciated serum half-lives increased from 1.7 h for uncon-
jugated IFN-a-2b to 7.3, 10.5, 19.9, and 23.9 h for the
respective PEG conjugates. Similarly, the half-life of
PEGylated human growth hormone increased from 1.4 to
6, 15, and 24 h upon conjugation to 2, 5, or 7.5 kDa PEG
constructs, respectively [29].
PEG molecules are available in different molecular
weight ranges (e.g., 1–100 kDa) and in both linear and
branched conformations, thereby enabling generation of a
protein conjugate with specific properties. PEG polymers
are relatively chemically inert, and have been shown to be
safe when used as fusion partners in injectable protein
therapeutics [30], in food and healthcare products (tooth-
paste can be up to 10 % PEG [31]), and as excipients in
various drug formulations [32]. Additional benefits of
PEGylation include reports that it reduces immunogenicity
[33], proteolysis [34], and protein aggregation [35]. Be-
cause of these advantageous properties, PEGylation was
chosen as the means of increasing the in vivo residence
time of filgrastim.
3.3 Strategies for PEGylation of Filgrastim
The first FDA-approved PEGylated proteins, Adagen and
Oncaspar, were heterogeneous multi-PEG mixtures that
differed in the number of attached chains and the site of
attachment [36]. From our work on a long-acting filgrastim
therapeutic, we came to the realization that having a con-
jugate with a single site of attachment would be preferred
as it would be easier to demonstrate consistency and pro-
vide proof of quality; however, the techniques and reagents
required for such a construct were still in development.
One strategy to achieve site-selective addition of a PEG
molecule available at the time was to target the free thiol
from an unpaired cysteine. G-CSF contains five cysteines;
however, four of these are involved in disulfide bonds and
would not be available for PEG conjugation. The remain-
ing cysteine (Cys 17) is not disulfide-linked but efforts to
attach a PEG molecule to this site resulted in decreased
activity. Structural analysis reveals that this cysteine is
located near the interior of the protein [37] and attachment
of the PEG molecule was likely disrupting the protein fold.
PEGylation of free amino groups is another strategy that
was evaluated. Free amino groups in proteins are present in
two instances: (1) the e-amino group from the side chain of
a lysine residue; or (2) the a-amino group from the
N-terminus of the protein. While there is typically only one
N-terminus per protein chain (provided the protein chain is
not cleaved to form multiple chains), lysines are frequently
found on the surface of proteins. This abundance of ac-
cessible amino groups can lead to multiple PEG additions.
For example, both Oncaspar and Adagen are PEGylated
at multiple sites: Oncaspar is reported to be PEGylated on
22 of its 33 free amino groups [38], and Adagen is re-
ported to be PEGylated on at least half of its 27 free amino
groups [39], although exact figures have not been released
by the Adagen manufacturer.
G-CSF contains five free amino groups including the
N-terminus and four lysines at positions 16, 23, 34, and 40.
Non-specific PEGylation of free amino groups in G-CSF
was an approach pursued by other research groups around
the same time as Amgen’s initial work to develop a long-
acting filgrastim (Ro 25-8315 and PEG-rHuG-CSF;
Table 3); however, none of these other early molecules has
gained regulatory approval. In one example, PEG was
added to filgrastim both at the four surface-exposed lysine
residues and the N-terminal methionine residue [40].
Analysis of this material revealed multiple species of
modified proteins with different molecular weights.
Another group used a mutated version of G-CSF (nar-
tograstim), in which several amino acids from the recom-
binant G-CSF have been replaced [41]. PEGylation of this
construct also resulted in multiple species of modified
G-CSF with different molecular weights.
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While our initial efforts also involved non-specific
PEGylation of free amino groups, our results suggested that
PEGylation of the lysine residues interfered with receptor
binding. Structural studies of the G-CSF/G-CSF-R com-
plex subsequently showed that two of these lysine residues
are located within the receptor-binding interface (Fig. 1)
[41]. In comparison, PEGylation of the N-terminus did not
significantly interfere with receptor binding; thus, for the
long-acting filgrastim, we pursued a means of selectively
PEGylating the a-amino group from the N-terminus.
Although the G-CSF/G-CSF-R (domains 1–3) structure
was not available when this choice was made, the co-
crystal structure has confirmed that the N-terminus is not
involved in the G-CSF/G-CSF-R interaction and is pointing
away from the ligand/receptor interface [42].
To achieve selective addition of the PEG moiety to the
N-terminal a-amino group and limit reaction with the
lysine e-amino groups, it was necessary to identify condi-
tions where the a-amino group (acid dissociation constant
[pKa] = 7.6–8.0 [43]) of the N-terminus was more reactive
than the lysine e-amino groups (pKa = 10.0–10.2 [43]).
This was achieved by lowering the pH of the reaction and
incorporating an optimized reactive PEG construct. In the
end, the process that was selected involved reductive
alkylation of G-CSF with a PEG aldehyde derivative at
pH 5.
3.4 Screening and Selection of an Appropriate
PEGylated Filgrastim
To select a long-acting filgrastim candidate for therapeutic
use, a large panel of PEG–G-CSF conjugates was gener-
ated and characterized. The PEG moieties that were
evaluated spanned a range of available molecular weight
polymers (12–30 kDa) and comprised both linear and
branched conformations. The extent of reaction was
monitored by high-performance liquid chromatography
(HPLC) to ensure a high percentage of conjugation, fol-
lowed by purification, and verification of the site of addi-
tion using endoproteinase peptide mapping and additional
physiochemical characterization [ultracentrifugation,
MALDI (matrix-assisted laser desorption/ionization) TOF
(time-of-flight) mass spectrometry, and size exclusion
HPLC with associated in-line light scattering]. This char-
acterization ensured appropriate composition, stoichio-
metry, and structure of the conjugates. More than 25
constructs were evaluated for in vitro and in vivo activity;
the in vitro activity score was derived from results in a cell-
based proliferation assay using cells stably expressing the
G-CSF-R and the in vivo activity score was based on the
area under the concentration–time curve (AUC) of the
ANC in healthy animals.
As shown in Fig. 2, there was a positive relationship
between the molecular weight of the added PEG and the
in vivo activity of the modified filgrastim. Similar results
were obtained by other researchers with PEGylated fil-
grastim or nartograstim [41, 44], whereby white blood cell
counts in mice were found to increase as the size or number
of PEG units was increased [55]. In those studies, like our
own, it was also observed that molecules with increased
in vivo activity demonstrated decreased in vitro activity. In
general, these characteristics became more magnified as
the molecular weight of the PEG molecule increased. The
decreased in vitro activity is likely a consequence of the
PEG molecule interfering directly and/or indirectly with
G-CSF binding to its receptor. This is likely a consequence
of the PEG molecule’s bulk and mobility which could
cause periodic occlusion of the binding interface, slowing
the on-rate of binding. A similar relationship between en-
hanced in vivo activity and decreased in vitro activity has
been observed for PEG conjugates of human growth hor-
mone [29] and asiolofetuin [45]. The result of our studies
Fig. 1 The N-terminus of granulocyte colony-stimulating factor (G-
CSF) is distal from the receptor binding site while lysine residues 16
and 23 are located in the receptor binding site. Left panel the
G-CSF:G-CSF receptor (G-CSF-R) signaling complex [42] comprises
two G-CSF (green) and two G-CSF-R molecules (light and dark
blue). The atoms of the G-CSF N-terminus are marked with yellow
balls. The atoms of lysines 16 and 23 are marked with pink balls.
Right panel a close-up of the interface providing more detail
regarding the location of lysines 16 and 23
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was the selection of an r-metHuG-CSF–PEG conjugate
containing a single linear 20 kDa PEG attached to the
N-terminal methionine. This construct would become
pegfilgrastim.
4 Pegfilgrastim
4.1 Non-Clinical Evaluation of Pegfilgrastim
Activity
The in vivo activity of pegfilgrastim compared to filgrastim
was evaluated in both normal and neutropenic mice by
subcutaneous (SC) injection. ANC is commonly used as a
pharmacodynamic marker because it is straightforward to
measure and represents the target cell for eliciting clinical
benefit in neutropenic patients. In normal mice a single
dose of pegfilgrastim (1000 lg/kg SC) increased the ANC
for 5 days, whereas a single injection of filgrastim at a
higher dose (2500 lg/kg SC) increased the ANC for only
1–2 days (Fig. 3a). In a model of chemotherapy-induced
neutropenia, control mice that received neither filgrastim
nor pegfilgrastim experienced 7 days of neutropenia,
whereas mice treated with either daily filgrastim (300 lg/
kg SC, days 2–11) or a single dose of pegfilgrastim
(1000 lg/kg SC) experienced only 2 days of neutropenia
(Fig. 3b). These data demonstrated that a single injection
of pegfilgrastim was as effective in stimulating neutrophil
recovery as multiple daily injections of filgrastim.
Pegfilgrastim exhibited an acceptable non-clinical
safety profile in short- and long-term studies across a
range of species—including rats, rabbits, and Cynomolgus
monkeys—using delivery by SC and intravenous routes.
By retaining filgrastim as the core of the molecule, a
predictable safety profile was possible because pegfil-
grastim, like endogenous G-CSF, is specific for only one
receptor. Furthermore, this safety profile shows that ad-
dition of the PEG molecule to filgrastim did not cause
significant qualitative changes in the filgrastim pharma-
cology/safety profile and no off-target toxicities were
identified.
Fig. 2 PEGylation-mediated increases in vivo activity were associ-
ated with decreases in vitro activity. The in vitro and in vivo activity
of various polyethylene glycol (PEG)–recombinant methionyl human
granulocyte colony-stimulating factor (G-CSF) (r-metHuG-CSF)
constructs were assessed and plotted according to the amount of
PEG added per molecule. For candidates that were pegylated at
multiple sites, the amount of PEG reflects the total molecular weight
of the PEG additions. Triangles indicate the proliferation induced in
cell line 32D clone 3 stably expressing human G-CSF receptor.
Squares indicate the weighted area under the concentration–time
curve (AUC) obtained from the daily average absolute neutrophil
count (ANC) from mice (n = 5/timepoint) weighted by multiplying
by the number of days after injection, then summed. The red triangle
and the red square mark the in vitro and in vivo activity of the
pegfilgrastim construct selected for further development. Reproduced
from Molineux [13] with permission of Springer Science ? Business
Media ( Birkauser Verlag/Switzerland)
Fig. 3 Pegfilgrastim has enhanced in vivo activity relative to
filgrastim. a Splenectomized mice were treated with a single injection
of carrier, filgrastim, or pegfilgrastim and the absolute neutrophil
count (ANC) was measured daily. Each timepoint represents 5–10
mice. b A single injection of pegfilgrastim is as effective as daily
injections of filgrastim at restoring a normal neutrophil count in mice
with chemotherapy-induced neutropenia. Neutropenia was induced in
mice using a single intravenous injection of 5-fluorouracil 150 mg/kg
on day 0. Mice were then randomized (n = 40 mice/group) and
treated with carrier, daily injections of filgrastim 300 lg/kg (days
2–11), or a single injection of pegfilgrastim 1000 lg/kg on day 2.
Daily ANC values were derived using four mice/group. Reproduced
from Molineux et al. [78] with permission from Elsevier ( 1999
International Society for Experimental Hematology)
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4.2 Pharmacokinetics of Pegfilgrastim
The pharmacokinetics of pegfilgrastim have been described
in recent review articles [46, 47] and are summarized
briefly here. The prolonged in vivo activity of pegfilgrastim
compared with filgrastim can be explained by the nearly
negligible role played by the kidneys in pegfilgrastim
clearance. The reduction in renal elimination was demon-
strated in bilaterally nephrectomized rats. In this model,
clearance of filgrastim 100 lg/kg was reduced by 75 % in
nephrectomized compared with sham-operated rats. By
comparison, clearance of pegfilgrastim 100 lg/kg was
similar in both the nephrectomized and sham-operated rats
(Fig. 4a) [48]. This clearly demonstrated that renal clear-
ance had been greatly reduced. To evaluate the role of the
kidney in pegfilgrastim clearance in humans, the pharma-
cokinetic profile for pegfilgrastim was evaluated in subjects
with varying degrees of renal function ranging from normal
to mildly, moderately, and severely impaired as well as
subjects with end-stage renal disease [49]. Across all
groups, the pharmacokinetic profile of pegfilgrastim was
similar (Fig. 4b), supporting the non-clinical observations
that the kidney contribution to clearance is negligible.
Addition of the 20 kDa PEG molecule increases both
the molecular weight and the size of filgrastim. The
molecular weight increases from 19 kDa (filgrastim) to
39 kDa (pegfilgrastim). This is still below the 60–70 kDa
molecular weight that is considered to be required to
avoid glomerular filtration and subsequent renal
elimination. The hydrodynamic radius, however, in-
creases approximately 2.5- to 3-fold (calculated using
equations in Fee and Van Alstine [50]). This increases
the size of filgrastim from *4 nm to *6 nm in diameter.
In general, proteins C6 nm in diameter (e.g., hemoglobin
6.4 nm and albumin 7 nm) avoid glomerular filtration
[25, 51]. With the reduction in renal clearance, the pri-
mary means of pegfilgrastim removal from the circulation
is by neutrophil-mediated clearance. Neutrophils and
neutrophil precursors express G-CSF-R. This receptor
binds pegfilgrastim and the drug–receptor complex is
internalized and degraded inside the cell. Support for this
hypothesis came from a comparison of pegfilgrastim
clearance in wild-type versus G-CSF-R-deficient mice. In
wild-type mice, serum concentrations of pegfilgrastim
remained elevated for less than 48 h following injection
of pegfilgrastim 10 lg/kg; whereas serum concentrations
of pegfilgrastim remained elevated for 144 h in G-CSF-R
knockout mice [52].
Another consequence of the G-CSF-R/pegfilgrastim in-
teraction is the stimulation of neutrophil precursor prolif-
eration and differentiation. Figure 5 demonstrates the
relationship between pegfilgrastim serum concentrations
and circulating neutrophils in breast cancer patients treated
with doxorubicin (60 mg/m2) and docetaxel (75 mg/m2),
followed by a single injection of pegfilgrastim (100 lg/kg)
Fig. 4 The kidney plays an insignificant role in pegfilgrastim
clearance. a Pharmacokinetic study in normal (sham-operated) and
bilaterally nephrectomized mice (adapted from Yang et al. [48]).
b Pharmacokinetic study in subjects with varying degrees of renal
function. Subjects (n = 6) were given a single subcutaneous dose of
pegfilgrastim 6 mg/kg. Data are presented as mean ± standard error
of the mean (adapted from Yang et al. [49]). Conc. concentration,
ESRD end-stage renal disease
Fig. 5 Serum pegfilgrastim concentrations and absolute neutrophil
count (ANC) profile in breast cancer patients treated with doxorubicin
(60 mg/m2), docetaxel (75 mg/m2), and a single administration of
pegfilgrastim (100 lg/kg). Reproduced from Holmes et al. [14] with
permission of Wiley Materials ( 2008 American College of Clinical
Pharmacology)
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1 day later [14]. After SC administration of pegfilgrastim,
serum concentrations of pegfilgrastim were sustained dur-
ing neutropenia. ANC levels started to increase after the
nadir on day 7, resulting in a rapid decline of serum con-
centrations of pegfilgrastim due to neutrophil-mediated
clearance. Thus, during chemotherapy-induced neutrope-
nia, circulating pegfilgrastim concentrations remain
elevated until there is an increase in the ANC, which leads
to increased pegfilgrastim consumption and self-regulated
clearance. In comparison, serum concentrations of filgras-
tim were rapidly cleared after each injection, and multiple
daily injections of filgrastim were required to maintain its
clinical efficacy [14]. A semi-mechanistic model that in-
cludes neutrophil-mediated clearance adequately describes
the relationship between pegfilgrastim serum concentra-
tions and the ANC profile in healthy subjects [53] and in
patients with non-small-cell lung cancer [54].
4.3 Clinical Efficacy of Pegfilgrastim
Pegfilgrastim is indicated to reduce the risk of FN in pa-
tients with non-myeloid malignancies receiving myelo-
suppressive chemotherapy. Approval of pegfilgrastim for
use in patients with chemotherapy-induced neutropenia
was based on results from two randomized, double-blind
phase III studies in patients with breast cancer, designed to
test the non-inferiority of pegfilgrastim versus filgrastim
[46, 47]. Similar results were observed in both trials,
demonstrating that a single fixed dose of pegfilgrastim per
chemotherapy cycle was at least equivalent to daily doses
of filgrastim in all efficacy endpoints including the duration
of severe neutropenia (ANC\0.5 9 109/L), the depth of
the ANC nadir in all cycles, the incidence of FN (neu-
tropenia plus fever/infection), and rates of hospitalization
and infection.
Subsequent clinical studies have shown pegfilgrastim to
be similarly effective across a range of regimens and tumor
types [15, 16, 55, 56]. Meta-analyses of clinical studies
have shown that pegfilgrastim reduces the risk of FN to a
significantly greater extent than filgrastim [57, 58] and that
pegfilgrastim also reduces the incidence of early mortality
during chemotherapy [57, 59]. Observational studies,
which include a broader range of patient populations than
those eligible for clinical trials, indicate that pegfilgrastim
is similarly effective in reducing FN risk in clinical prac-
tice [60, 61].
Unlike filgrastim, pegfilgrastim is not approved for
stem cell mobilization, but clinical studies have shown
that it is at least as effective as daily G-CSFs in mobi-
lization of peripheral blood stem/progenitor cells and
engraftment in the autologous and allogeneic setting
[62–65].
4.4 Clinical Safety of Pegfilgrastim
Clinical safety data derived from the various clinical trials
show that the safety profile of pegfilgrastim is comparable
to that of filgrastim in terms of the total incidence of ad-
verse events, incidence of adverse events attributed to
study drug, and withdrawals due to adverse events. As with
all G-CSFs, the most common adverse effect is bone pain,
which is generally mild to moderate and manageable with
non-narcotic analgesics. A patient-level analysis across
multiple studies found that bone pain was experienced by
more patients treated with pegfilgrastim than placebo, but
that incidence of bone pain was similar between the peg-
filgrastim- and filgrastim-treated groups [66]. Serious ad-
verse reactions occur more rarely, and include splenic
rupture, acute respiratory distress syndrome, allergic reac-
tions, and potential for tumor growth stimulation effects on
malignant cells [67]. As with all protein biologics, the
potential for immunogenicity also exists, but neutralizing
antibodies to pegfilgrastim have not been reported in
clinical studies.
5 Future Perspectives
Pegfilgrastim was the only commercially available long-
acting G-CSF for more than 10 years, until the European
approval of lipegfilgrastim in 2013 through the demon-
stration of clinical non-inferiority to pegfilgrastim in a
randomized phase III study in patients with breast cancer
[68]. Lipegfilgrastim is PEGylated on the O-linked glyco-
sylation site at Thr-134; however, because this site is
heterogeneously glycosylated when G-CSF is expressed in
mammalian cells, the polysaccharide is added to the G-CSF
protein core enzymatically using two recombinant glyco-
syltransferase enzymes and activated sugar nucleotide
donor substrates in vitro. Subsequently, the PEG molecule
is covalently attached to the polysaccharide [69].
Other PEGylated G-CSFs have been tested (Table 3),
but few examples of approaches to extend the half-life of
G-CSF exist outside of PEGylation. The most clinically
advanced non-PEGylated molecules are benefilgrastim,
which is a recombinant fusion protein of human Fc and
G-CSF produced in mammalian cells [70] and balugrastim,
which is a recombinant fusion protein of human serum
albumin and G-CSF produced in yeast [71]. Benefilgrastim,
which comprises two chains of human G-CSF-Fc, has re-
cently been evaluated in a phase II study in patients with
breast cancer [72]. In this study, benefilgrastim adminis-
tered once per cycle at 240 or 320 lg/kg SC provided
neutrophil support with a safety profile similar to that of
pegfilgrastim during multiple chemotherapy cycles.
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Balugrastim has demonstrated non-inferiority to pegfil-
grastim in a phase III study in patients with breast cancer,
but it has not been approved for commercial use in either
the USA or Europe. Since these molecules are administered
in an identical manner to pegfilgrastim (injected once per
chemotherapy cycle) and have not demonstrated superior
clinical efficacy or safety, they may be better characterized
as alternatives to pegfilgrastim rather than therapeutic
advances.
Innovations in drug delivery provide additional possi-
bilities for therapeutic improvements. Pegfilgrastim should
be administered the day after chemotherapy [11] to avoid
the risk of stimulating proliferation of myeloid progenitor
cells in the presence of cytotoxic chemotherapy agents and
worsening neutropenia outcomes [17]. Nonetheless, same-
day administration of pegfilgrastim is observed in clinical
practice [73], most likely due reasons of logistics or con-
venience. To overcome this problem, an on-body injector
has been developed—a programmable delivery device at-
tached to the patient’s skin to deliver pegfilgrastim the day
after chemotherapy—that eliminates the requirement for a
patient to return to the clinic to receive pegfilgrastim [74].
This device, which was recently approved by the FDA
(tradename OnPRO), may therefore increase patient com-
pliance and increase the efficacy of pegfilgrastim in clinical
practice.
Although not necessarily long-acting, small molecules
capable of stimulating the G-CSF-R signaling pathway can
provide the option of orally administered G-CSF, which
may appeal to some patients. Several groups are pursuing
this approach and have demonstrated in vitro and in vivo
activity in preclinical studies [75–77], although currently
they are in the early stages of clinical development. Clearly
more work is needed in this area, including studies in hu-
man subjects and clinical testing against the available
protein-based G-CSF products.
6 Conclusion
Filgrastim is a widely used short-acting G-CSF with a
long-standing record of clinical efficacy and safety. To
eliminate the need for daily injections and to maintain a
similar safety profile, a long-acting form of filgrastim was
designed that retained the core protein with additions to
increase the molecular size and extend the circulating half-
life. PEGylation was considered useful for therapeutic
proteins: it is non-toxic; it can improve properties related to
immunogenicity, stability, and aggregation; and it can en-
hance the pharmacokinetic/pharmacodynamic profiles as a
conjugation partner. In addition, technology has been de-
veloped so that it can be added to specific sites on the
protein to limit the potential for interference with receptor
binding, and it is possible generate PEG moieties with a
range of sizes to enable selection of a modified protein with
optimal pharmacokinetic/pharmacodynamic profiles. Peg-
filgrastim contains a single linear 20 kDa PEG attached to
the N-terminal amino acid of filgrastim, and the pharma-
cokinetic profile has been sufficiently improved by sig-
nificantly reducing the renal clearance. As such, a single
dose of pegfilgrastim effectively reduces the risk of neu-
tropenia and neutropenia-associated complications for an
entire chemotherapy cycle.
Acknowledgments Tara Arvedson, James O’Kelly, and Bing-Bing
Yang are employees of and own stocks in Amgen Inc., the
manufacturer of filgrastim and pegfilgrastim.
Author contributions Tara Arvedson conceived the idea for the
manuscript, wrote the first draft, and is the guarantor for the overall
content. James O’Kelly and Bing–Bing Yang wrote and edited sub-
sequent drafts of the manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and
indicate if changes were made.
References
1. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-
metHuG-CSF): the first 10 years. Blood. 1996;88(6):1907–29.
2. Donadieu J, Leblanc T, Bader Meunier B, et al. French Severe
Chronic Neutropenia Study Group. Analysis of risk factors for
myelodysplasias, leukemias and death from infection among
patients with congenital neutropenia. Experience of the French
Severe Chronic Neutropenia Study Group. Haematologica.
2005;90(1):45–53.
3. Dancey J, Deubelbeiss KA, Harker LA, et al. Neutrophil kinetics
in man. J Clin Invest. 1976;58(3):705–15.
4. Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with
2H2O reveals a human neutrophil lifespan of 5.4 days. Blood.
2010;116(4):625–7.
5. Ogawa M. Differentiation and proliferation of hematopoietic
stem cells. Blood. 1993;81:2844–53.
6. Arvedson T, Molineux G. Use of r-metHuG-CSF to enable che-
motherapy delivery for solid tumors, in twenty years of G-CSF.
In: Molineux G, Foote M, Arvedson T, editors. Twenty Years of
G-CSF. Clinical and nonclincal discoveries. Springer; 2012.
p. 151–68.
7. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cy-
clophosphamide, methotrexate, and fluorouracil in node-positive
breast cancer—the results of 20 years of follow-up. N Engl J
Med. 1995;332(14):901–6.
8. Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of an-
thracycline-based chemotherapy in the adjuvant setting improves
outcome of breast cancer patients. Breast Cancer Res Treat.
2009;114(3):479–84.
9. Agboola O, Crawford J, Dale D, et al. Most patients treated with
adjuvant chemotherapy for breast cancer receive substantially
Development of a long-acting G-CSF 195
reduced dose intensity [abstract no. 110]. American Society of
Clinical Oncologists (ASCO), 31 May–3 Jun 2003, Chicago.
10. Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and
pharmacodynamics of a recombinant human granulocyte colony-
stimulating factor. Drug Metab Rev. 1996;28(4):625–58.
11. Amgen. Neupogen (filgrastim): US prescribing information.
Thousand Oaks: Amgen Inc.; 2007.
12. Green MD, Koelbl H, Baselga J, et al. A randomized double-
blind multicenter phase III study of fixed-dose single-adminis-
tration pegfilgrastim versus daily filgrastim in patients receiving
myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35.
13. Molineux G. Pegfilgrastim - designing an improved form of
rmetHu-GCSF. In: Veronese FM, editor. Pegylated protein drugs:
basic science and clinical applications. Basel: Birkhauser; 2009.
p. 169–85.
14. Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable ef-
ficacy and safety profiles of once-per-cycle pegfilgrastim and
daily injection filgrastim in chemotherapy-induced neutropenia: a
multicenter dose-finding study in women with breast cancer. Ann
Oncol. 2002;13(6):903–9.
15. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer pa-
tients receiving chemotherapy benefit from first-cycle pegfil-
grastim. Oncologist. 2007;12(12):1416–24.
16. Hecht JR, Pillai M, Gollard R, et al. A randomized, placebo-
controlled phase ii study evaluating the reduction of neutropenia
and febrile neutropenia in patients with colorectal cancer re-
ceiving pegfilgrastim with every-2-week chemotherapy. Clin
Colorectal Cancer. 2010;9(2):95–101.
17. Burris HA, Belani CP, Kaufman PA, et al. Pegfilgrastim on the
same day versus next day of chemotherapy in patients with breast
cancer, non–small-cell lung cancer, ovarian cancer, and non-
hodgkin’s lymphoma: results of four multicenter, double-blind,
randomized phase II studies. J Oncol Pract. 2010;6(3):133–40.
18. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and sub-
sequent cycle use of pegfilgrastim prevents febrile neutropenia in
patients with breast cancer: a multicenter, double-blind, placebo-
controlled phase III study. J Clin Oncol. 2005;23(6):1178–84.
19. Molineux G. The design and development of pegfilgrastim (PEG-
rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10:1235–44.
20. Renwick W, Pettengell R, Green M. Use of filgrastim and peg-
filgrastim to support delivery of chemotherapy. BioDrugs.
2009;23(3):175–86.
21. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte
colony-stimulating factor of fever and neutropenia induced by
chemotherapy in patients with small-cell lung cancer. N Engl J
Med. 1991;325(3):164–70.
22. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant
granulocyte colony stimulating factor reduces the infectious
complications of cytotoxic chemotherapy. Eur J Cancer.
1993;29(3):319–24.
23. Raso SW, Abel J, Barnes JM, et al. Aggregation of granulocyte-
colony stimulating factor in vitro involves a conformationally
altered monomeric state. Protein Sci. 2005;14(9):2246–57.
24. Ohlson M, So¨rensson J, Lindstro¨m K, et al. Effects of filtration
rate on the glomerular barrier and clearance of four differently
shaped molecules. Am J Physiol Renal Physiol.
2001;281(1):F103–13.
25. Sarin H. Physiologic upper limits of pore size of different blood
capillary types and another perspective on the dual pore theory of
microvascular permeability. J Angiogenes Res. 2010;2:14.
26. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals.
Nat Rev Drug Discov. 2003;2(3):214–21.
27. Sherman MR, et al. Conjugation of high-molecular weight
poly(ethylene glycol) to cytokines: granulocyte-macrophage
colony-stimulating factors as model substrates. In: Harris JM,
Zalipsky S, editors. Poly(ethylene glycol). American Chemical
Society, San Francisco, CA, 1997. p. 155–69.
28. Kusterle M, Jevsevar S, Porekar VG. Size of pegylated protein
conjugates studied by various methods. Acta Chim Slov.
2008;55:594–601.
29. Clark R, Olson K, Fuh G, et al. Long-acting growth hormones
produced by conjugation with polyethylene glycol. J Biol Chem.
1996;271(36):21969–77.
30. Kontermann R. Half-life modulating strategies—an introduction.
In: Kontermann R, editor. Therapeutic proteins: strategies to
modulate their plasma half-lives. Weinheim: Wiley-Blackwell;
2012. p. 3–21.
31. Fruijtier-Polloth C. Safety assessment on polyethylene glycosols
(PEGs) and their derivaties as used in cosmetic products. Tox-
icology. 2005;214:1–38.
32. Working PK, Newman MS, Johnson J, et al. Safety of poly(-
ethylene glycol) and poly(ethylene glycol) derivatives. In: Harris
JM, Zalipsky S, editors. Poly(ethylene glycol): chemistry and
biological applications. Washington, DC: ACS Books; 1997.
p. 45–54.
33. Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we
stand? Expert Opin Biol Ther. 2009;9(1):111–9.
34. Fishburn CS. The pharmacology of PEGylation: balancing PD
with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):
4167–83.
35. Piedmonte DM, Treuheit MJ. Formulation of Neulasta (pegfil-
grastim). Adv Drug Deliv Rev. 2008;60(1):50–8.
36. Zalipsky S. Chemistry of polyethylene glycol conjugates with
biologically active molecules. Adv Drug Deliv Rev.
1995;16(2–3):157–82.
37. Arakawa T, Prestrelski SJ, Narhi LO, et al. Cysteine 17 of re-
combinant human granulocyte-colony stimulating factor is par-
tially solvent-exposed. J Protein Chem. 1993;12(5):525–31.
38. Zhao H, Greenberger L, Horak I. Drug conjugates with poly(-
ethylene glycol). In: Kratz F, Senter P, Steinhagen H, editors.
Drug delivery in oncology: from basic research to cancer therapy.
Weinheim: Wiley; 2013. p. 627–66.
39. Davis F. PEG-adenosine deaminase and PEG-asparaginase, In:
Maeda H, Kabanov A, Kataoka K, et al., editors. Polymer drugs
in the clinical stage: advances in experimental medicine and bi-
ology. New York: Springer USA; 2003. p. 51–8.
40. Satake-Ishikawa R, Ishikawa M, Okada Y, et al. Chemical
modification of recombinant human granulocyte colony-s-
timulating factor by polyethylene glycol increases its biological
activity in vivo. Cell Struct Funct. 1992;17(3):157–60.
41. Yamasaki M, Asano M, Okabe M, et al. Modification of re-
combinant human granulocyte colony-stimulating factor (rhG-
CSF) and its derivative ND 28 with polyethylene glycol.
J Biochem. 1994;115:814–9.
42. Tamada T, Honjo E, Maeda Y, et al. Homodimeric cross-over
structure of the human granulocyte colony-stimulating factor
(GCSF) receptor signaling complex. Proc Natl Acad Sci USA.
2006;103(9):3135–40.
43. Wong S. Reactive groups of proteins and their modifying agents.
In: Chemistry of protein conjugations and cross-linking. Boca
Raton: CRC Press, Inc.; 1991. p. 7–45.
44. Bowen S, Tare N, Inoue T, et al. Relationship between molecular
mass and duration of activity of polyethylene glycol conjugated
granulocyte colony-stimulating factor mutein. Exp Hematol.
1999;27(3):425–32.
45. Roseng L, Tolleshaug H, Berg T. Uptake, intracellular transport,
and degradation of polyethylene glycol-modified asialofetuin in
hepatocytes. J Biol Chem. 1992;267(32):22987–93.
46. Yang B-B, Kido A. Pharmacokinetics and pharmacodynamics of
pegfilgrastim. Clin Pharmacokinet. 2011;50(5):295–306.
196 T. Arvedson et al.
47. Yang BB, Savin MA, Green M. Prevention of chemotherapy-
induced neutropenia with pegfilgrastim: pharmacokinetics and
patient outcomes. Chemotherapy. 2012;58(5):387–98.
48. Yang B-B, Lum PK, Hayashi MM, et al. Polyethylene glycol
modification of filgrastim results in decreased renal clearance of
the protein in rats. J Pharm Sci. 2004;93(5):1367–73.
49. Yang B-B, Kido A, Salfi M, et al. Pharmacokinetics and phar-
macodynamics of pegfilgrastim in subjects with various degrees
of renal function. J Clin Pharmacol. 2008;48(9):1025–31.
50. Fee CJ, Van Alstine JM. Prediction of the viscosity radius and the
size exclusion chromatography behavior of PEGylated proteins.
Bioconjug Chem. 2004;15:1304–13.
51. Fujigaki Y, Nagase M, Kobayasi S, et al. Intra-GBM site of the
functional filtration barrier for endogenous proteins in rats. Kid-
ney Int. 1993;43(3):567–74.
52. Kotto-Kome AC, Fox SE, Lu W, et al. Evidence that the
granulocyte colony-stimulating factor (G-CSF) receptor plays a
role in the pharmacokinetics of G-CSF and PegG-CSF using a
G-CSF-R KO model. Pharmacol Res. 2004;50(1):55–8.
53. Roskos LK, Lum P, Lockbaum P, et al. Pharmacokinetic/phar-
macodynamic modeling of pegfilgrastim in healthy subjects.
J Clin Pharmacol. 2006;46(7):747–57.
54. Yang BB. Integration of pharmacokinetics and pharmacody-
namics into the drug development of pegfilgrastim, a pegylated
protein. In: Meibohm B, editor. Pharmacokinetics and pharma-
codynamics of biotech drugs: principles and case studies in drug
development. Weinheim: Wiley-Blackwell; 2006. p. 373–93.
55. Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, random-
ized study of pegfilgrastim vs. daily filgrastim as an adjunct to
chemotherapy in elderly patients with non-Hodgkin’s lymphoma.
Leuk Lymphoma. 2003;44:1503–8.
56. Pinter T, Abella, S, Cesas A et al. Results of a phase III, ran-
domized, double-blind, placebo-controlled trial of pegfilgrastim
(PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI
and bevacizumab (B) for colorectal cancer (CRC) [abstract no.
3575]. J Clin Oncol. 2013. 31(Suppl 4):LBA445.
57. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary
prophylaxis with granulocyte colony-stimulating factor on febrile
neutropenia and mortality in adult cancer patients receiving
chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):
3158–67.
58. Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-s-
timulating factors for febrile neutropenia prophylaxis following
chemotherapy: systematic review and meta-analysis. BMC Can-
cer. 2011;11:404.
59. Lyman H, Kuderer NM, Crawford, J et al. Impact of pegfilgrastim
on early all-cause mortality in patients receiving cancer che-
motherapy [abstract]. J Clin Oncol. 2008;26(Suppl):6552.
60. Almenar C, Bosch Roig C, Jime´nez Orozco E, et al. LEARN II
Study Group. Effectiveness of daily versus non-daily granulocyte
colony-stimulating factors in patients with solid tumours under-
going chemotherapy: a multivariate analysis of data from current
practice. Eur J Cancer Care (Engl). 2013;22(3):400–12.
61. Hershman D, Hurley D, Wong M, et al. Impact of primary pro-
phylaxis on febrile neutropenia within community practices in the
US. J Med Econ. 2009;12(3):203–10.
62. Ocheni S, Zabelina T, Bacher U, et al. Pegfilgrastim compared to
lenograstim after allogeneic peripheral blood stem-cell transplan-
tation from unrelated donors. Leuk Lymphoma. 2009;50(4):612–8.
63. Cesaro S, Nesi F, Tridello G, et al. A randomized, non-inferiority
study comparing efficacy and safety of a single dose of pegfil-
grastim versus daily filgrastim in pediatric patients after au-
tologous peripheral blood stem cell transplant. PLoS One.
2013;8(1):e53252.
64. Gerds A, Fox-Geiman M, Dawravoo K, et al. Randomized phase
III trial of pegfilgrastim versus filgrastim after autologus
peripheral blood stem cell transplantation. Biol Blood Marrow
Transplant. 2010;16(5):678–85.
65. Willis F, Woll P, Theti D, et al. Pegfilgrastim for peripheral
CD34? mobilization in patients with solid tumours. Bone Mar-
row Transplant. 2009;43(12):927–34.
66. Gregory SA, Schwartzberg LS, Mo M et al. Evaluation of re-
ported bone pain in cancer patients receiving chemotherapy in
pegfilgrastim clinical trials: a retrospective analysis. Community
Oncology. 2010;7(7):297–308.
67. Amgen. Neulasta (pegfilgrastim): full prescribing information.
Thousand Oaks: Amgen Inc.; 2014.
68. Bondarenko I, Gladkov OA, Elsaesser R, et al. Efficacy and
safety of lipegfilgrastim versus pegfilgrastim: a randomized,
multicenter, active-control phase 3 trial in patients with breast
cancer receiving doxorubicin/docetaxel chemotherapy. BMC
Cancer. 2013;13:386.
69. European Medicines Agency. Lonquex: EPAR product informa-
tion: summary of product characteristics. London: European
Medicines Agency; 2013.
70. Cox GN, Chlipala EA, Smith DJ, et al. Hematopoietic properties
of granulocyte colony-stimulating factor/immunoglobulin (G-
CSF/IgG-Fc) fusion proteins in normal and neutropenic rodents.
PLoS One. 2014;9(3):e91990.
71. Avisar N, Adar L, Bock J, et al. First-in-human, phase I/IIa dose-
escalation and safety study of balugrastim in breast cancer pa-
tients receiving myelosuppressive chemotherapy. Cancer Che-
mother Pharmacol. 2015;75(5):929–39.
72. Glaspy J, Tang T, Rutty D, et al. A phase II, randomized, multi-
centre, open-label, active-controlled, dose-finding trial of F-627
(benefilgrastim) in women with breast cancer receiving myelo-
toxic chemotherapy [abstract no. 1584]. In: 56th annual meeting
of the American Society of Hematology; 6–9 Dec 2014; San
Francisco.
73. Weycker D, Wu H, Hagiwara M, et al. Use of chemotherapy and
same-day pegfilgrastim prophylaxis in US clinical practice [ab-
stract no. 4825]. In: 56th annual meeting of the American Society
of Hematology; 6–9 Dec 2014; San Francisco.
74. Yang BB, Morrow PK, Wu X, Moxness M, Padhi D et al.
Comparison of pharmacokinetics and safety of pegfilgrastim
administered by two delivery methods: on-body injector and
manual injection with a prefilled syringe. Cancer Chemother
Pharmacol. 2015;1–8. doi:10.1007/s00280-015-2731-x.
75. Marschke K, Vajda E, Zhi L. Novel small-molecule human
G-CSF receptor agonist stimulates neutrophil counts in monkeys
and displays anti-proliferative effects on tumor cells mediated by
a reduction of intracellular iron [abstract no. 3462]. In: 55th an-
nual meeting of the American Society of Hematology;7–10 Dec
2013; New Orleans.
76. Kusano K, Ebara S, Tachibana K, et al. A potential therapeutic
role for small nonpeptidyl compounds that mimic human
granulocyte colony-stimulating factor. Blood. 2004;103:836–42.
77. Tian S-S, Lamb P, King AG, et al. A small, nonpeptidyl mimic of
granulocyte-colony-stimulating factor. Science. 1998;281(5374):
257–9.
78. Molineux G, Kinstler O, Briddell B, et al. A new form of Fil-
grastim with sustained duration in vivo and enhanced ability to
mobilize PBPC in both mice and humans. Exp Hematol.
1999;27(12):1724–34.
79. Viens P, Maraninchi D. High-dose chemotherapy in advanced
breast cancer. Crit Rev Oncol Hematol. 2002;41(2):141–9.
80. Salafet O, Ruzina ND, Ponomarenko NA, et al. Diagnostic and
pathogenetic implications of the site specificity of antibody pro-
teases in multiple sclerosis [in Russian]. Vestn Ross Akad Med
Nauk. 2010;4:8–15.
81. Scholz M, Engel C, Apt D, et al. Pharmacokinetic and pharma-
codynamic modelling of the novel human granulocyte colony-
Development of a long-acting G-CSF 197
stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.
Cell Prolif. 2009;42(6):823–37.
82. Schwartzberg L, Sankar SL, Apt D, et al. An open-label, dose-
escalating study of Maxy-G34, a novel potent, long-acting pe-
gylated G-CSF, compared with pegfilgrastim (PF) for the treat-
ment of chemotherapy induced neutropenia (CIN) [abstract no.
e14500]. American Society of Clinical Oncology annual meeting;
29 May–2 Jun 2009; Orlando.
83. Tanaka H, Kaneko T. Pharmacokinetic and pharmacodynamic
comparisons between human granulocyte colony-stimulating
factor purified from human bladder carcinoma cell line 5637
culture medium and recombinant human granulocyte colony-s-
timulating factor produced in Escherichia coli. J Pharmacol Exp
Ther. 1992;262(1):439–44.
84. Scaramuzza S, Tonon G, Olianas A, et al. A new site-specific
monoPEGylated filgrastim derivative prepared by enzymatic
conjugation: production and physicochemical characterization.
J Control Release. 2012;164(3):355–63.
198 T. Arvedson et al.
